Dipeptide Diaminobutyroyl Benzylamide Diacetate
Skin / Anti-AgingAlso known as: SYN-AKE, Snake Venom Peptide
Mechanism
A synthetic peptide inspired by the venom of the temple viper (Tropidolaemus wagleri). It relaxes facial muscles by blocking the nerve-to-muscle signal, similar to how Botox works but applied topically. Clinical studies by Pentapharm showed up to 52% reduction in wrinkle depth in 28 days. Often marketed as "topical Botox" in cosmetics.
Technical detail
Synthetic tripeptide mimetic of waglerin-1 (a 22-amino acid peptide from Tropidolaemus wagleri venom). Acts as a reversible antagonist of the muscular nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction. Competes with acetylcholine for binding at the alpha-1 subunit, reducing muscle contraction frequency and intensity. Unlike botulinum toxin (which cleaves SNARE proteins), SYN-AKE acts postsynaptically. Pentapharm in-vivo study (45 volunteers): 52% wrinkle depth reduction at 28 days (2x/day application). Effective at 4% concentration in formulations.
Effects
## Integumentary System — Neuromuscular Wrinkle Reduction [Tier 2 — Moderate Human Data] Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic tripeptide designed to mimic waglerin-1, a peptide isolated from the Temple Viper (Tropidolaemus wagleri). Waglerin-1 is a competitive antagonist at the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction — the same receptor targeted by curare-type compounds. By blocking nAChR, Syn-Ake reduces the frequency and intensity of muscle contraction at the application site, smoothing expression lines similarly to botulinum toxin (but through a receptor-blocking mechanism rather than SNARE complex inhibition). In clinical studies, Syn-Ake reduced wrinkle depth by 52% after 28 days of twice-daily application at 4% concentration — the highest wrinkle reduction reported for any topical peptide. It is functionally complementary to Argireline (which targets the presynaptic side via SNARE) while Syn-Ake targets the postsynaptic side (nAChR). ## Neuromuscular System — Local Effects [Tier 2 — Mechanistic Data] The nAChR antagonism is confined to superficial tissue penetrated by the peptide. No systemic neuromuscular effects. The small molecular weight (~563 Da) and the diaminobutyroyl modification enhance skin penetration compared to the native waglerin peptide (which is a 22-amino acid peptide that would not penetrate skin).
Practitioner Guide
## Practical Formulation Guide ### Why Syn-Ake Is Special Syn-Ake attacks expression lines from the opposite side of the neuromuscular junction compared to Argireline: - **Argireline:** Presynaptic — reduces neurotransmitter release (SNARE complex inhibition) - **Syn-Ake:** Postsynaptic — blocks the muscle's ability to respond to acetylcholine (nAChR antagonism) - **Combined:** The two mechanisms are additive. Using both Argireline + Syn-Ake together is the most effective topical approach to expression line reduction. ### Effective Concentrations - **Optimal:** 4% of commercial Syn-Ake solution. This is the concentration used in clinical studies showing 52% wrinkle reduction. - **Minimum effective:** 1-2% of commercial solution. ### Formulation Considerations - **pH:** Stable at pH 5.0-7.0. - **Compatibility:** Compatible with Argireline (complementary mechanisms), Matrixyl, and other cosmetic peptides. Compatible with niacinamide, hyaluronic acid, ceramides. - **Vehicle:** Water-soluble. Best in aqueous serums. - **Caution:** The peptide is sensitive to UV light. Formulations should be packaged in opaque or amber containers. Do not use in products exposed to direct sunlight. ### The Ultimate Expression Line Serum For maximum topical wrinkle reduction, combine: 1. **Syn-Ake 4%** (postsynaptic nAChR blockade) 2. **Argireline 10%** (presynaptic SNARE inhibition) 3. **SNAP-8 / Acetyl Octapeptide-3 (if available)** — enhanced version of Argireline This combination targets both sides of the neuromuscular junction — the closest topical approach to Botox. ### Realistic Expectations - **2 weeks:** Subtle smoothing of fine expression lines. May be noticeable in photographs. - **4 weeks:** 20-52% wrinkle depth reduction (clinical studies). Upper range with 4% concentration applied twice daily to expression lines. - **8+ weeks:** Maintained or slightly improved results. Unlike Botox, results do not "wear off" suddenly but gradually reverse if product is discontinued. - **Comparison to Botox:** Syn-Ake + Argireline combination achieves approximately 30-40% of Botox-level wrinkle reduction. Not a replacement for moderate-to-severe expression lines, but an excellent maintenance strategy between Botox appointments.
Research Summary
## Tier 1 — Strong Clinical Evidence - Well-characterized mechanism: nicotinic acetylcholine receptor competitive antagonism (confirmed in receptor binding studies and electrophysiology) - Widely used commercial ingredient with established safety record ## Tier 2 — Moderate Evidence - Clinical study (Pentapharm/DSM): 52% wrinkle depth reduction after 28 days at 4% concentration in twice-daily application (n=45, instrumentally measured) - Synergistic effect with Argireline (presynaptic + postsynaptic targeting) — the most effective topical wrinkle approach available - Well-tolerated with no reports of systemic neuromuscular effects ## Tier 3 — Preclinical/Theoretical - The 52% wrinkle reduction claim, while from an instrumentally-measured study, is from a manufacturer-sponsored trial. Independent replication at this magnitude would strengthen confidence. - Enhanced delivery systems may push efficacy closer to injectable neurotoxin levels — not yet demonstrated - Long-term safety of chronic topical nAChR blockade not formally studied (but no concerns from years of commercial use)